Artificial Intelligence/Machine Learning Research in Hemophilia

Funding Agency:
Pfizer Inc.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

Projects that will be considered for Pfizer support will focus on Artificial Intelligence/Machine Learning in the areas mentioned below. Projects with a focus on emerging potential one-time treatments such as genetic medicine/gene transfer will be preferentially considered.

• Research studies that develop artificial intelligence/machine learning methods, tools and/or apps to use patient data on, for example, infusions, bleeds, laboratory factors and lifestyle to assist clinicians in treatment selection o a focus on emerging potential one-time treatments such as genetic medicine/gene transfer is strongly preferred

• Research studies that develop AI/ML methods and tools to increase the ability to predict disease risk; identify disease severity and progression due to morbidity from joint disease or recurrent bleeding; and/or improve disease management for persons with hemophilia (PWH) including optimizing treatment for patients with high bleeding risk (e.g., severe hemophilia)

• Research projects that develop AI/ML methods and tools to enhance patient engagement with the local hemophilia treatment center and maximize follow-up after potential one-time treatments such as gene therapy, including for patients living in remote or geographically distant areas

• Research projects that develop intelligent educational tools and platforms, leveraging AI/ML to deliver innovative educational and training programs for patients, caregivers, clinicians, healthcare providers, researchers, regulatory agencies and policy makers to increase knowledge sharing, awareness and advocacy for hemophilia o a focus on emerging potential one-time treatments such as genetic medicine/gene transfer is strongly preferred

• Research studies that leverage AI/ML to enhance data surveillance and increase collaboration among data partners and the ability to collect PWH-related data in real time and to link useful real world data from diverse sources (e.g., claims, EHR, registry, patient-reported outcomes, patient-level channels such as wearable devices, mobile apps, sensors) to advance the understanding of hemophilia disease progression, treatment outcomes, factors influencing prognosis and quality of life, evidence on resource utilization, etc.

• Develop a recommendation system leveraging AI-NLP approach and published literature and scientific evidence to offer more personalized guidelines and algorithms to monitor adherence and outcomes.

Proposal Deadline: *September 10, 2020 [Deadline Extended]

Agency Website

Eligibility Requirements

Geographic Scope • United States

To be eligible: • The institution and principal investigator (PI) must be based in one of the eligible countries noted above. • Only organizations are eligible to receive grants, not individuals or medical practice groups. • Applicant must be affiliated with a host institution



Amount Description

Individual projects requesting up to $350,000-450,000 will be considered. Pfizer anticipates awarding up to 1 grant • The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the approval notification

Funding Type





Engineering and Physical Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

September 10, 2020